Form D · Biotechnology
KPI Therapeutics, Inc.
Seattle, WA · CIK 0001607700
Offering snapshot reported Dec 5, 2016 · SEC filing
- Reported sold
- $18K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Dec 2, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 5, 2016 | Initial | $18,000 | No comparison | 1 | SEC filing |
| Feb 16, 2016 | Initial | $50,500 | No comparison | 1 | SEC filing |
| May 19, 2015 | Initial | $27,000 | No comparison | 2 | SEC filing |
| May 16, 2014 | Initial | $1,627,498 | No comparison | 43 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-275603
Source: Form D, filed Dec 5, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ray Bartoszek | Director |
| Magness L. Charles | Director, Executive |
| Thomas E Hornish | Executive |
| Shawn Iadonato | Director |
| Blake Ilstrup | Executive |
| Charles L. Magness | Director, Executive |
| Don Merlino | Director |
| Steven Mitchel | Director |
| Craig Philips | Executive |
| James G. W. Reed | Director |
| Paul Sylvester | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
401 Terry Avenue North, 4 Th Floor
Seattle, WA, 98109-5208
Seattle, WA, 98109-5208